Table 1.
Characteristics of the study population.
| Total Population | n = 166 | |
|---|---|---|
| Sex ratio M:F (%F *) | 128:38 (22.9%) | |
| Age, years ** | 52.5 (42–59) | |
| Calendar year of HIV diagnosis ** | 2009 (2003–2013) | |
| Nadir CD4+, cell/mmc ** | 293 (172–414) | |
| HBcAb-positive * | 58 (34.9%) | |
| CD4+ cell/mmc at 2DR switch ** | 695 (547–880) | |
| Triple ART drug classes composition *: | ||
| Two NRTIs + PI | 65 (39.2%) | |
| Two NRTIs +NNRTI | 38 (22.9%) | |
| Two NRTIs + INI | 56 (33.7%) | |
| Other | 7 (4.2%) | |
| 2DR composition *: | ||
| 3TC + PI | 59 (35.5%) | |
| 3TC + DTG | 107 (64.5%) | |
| HIV-RNA copies/mL 24 months before 2DR switch *: | ||
| pts <20 copies/ml | 130 (78.3%) | |
| pts <20 copies/mL target detected | 36 (21.7%) | |
| HIV-RNA copies/mL 12 months before 2DR switch *: | ||
| pts <20 copies/ml | 133 (80.1%) | |
| pts <20 copies/mL target detected | 33 (19.8%) | |
| HIV RNA at 2DR switch *: | ||
| pts <20 copies/ml | 126 (75.9%) | |
| pts <20 copies/mL target detected | 36 (31.7%) | |
| Not available | 4 (2.4%) | |
| HIV RNA 6 months post-2DR switch * | ||
| pts <20 copies/ml | 129 (77.7%) | |
| pts <20 copies/mL target detected | 37 (22.3%) | |
| HIV RNA 12 months post-2DR switch *††: | ||
| pts <20 copies/ml | 74 (50.4%) | |
| pts <20 copies/mL target detected | 43 (29.9%) | |
| pts detectable >20 copies/ml | 27 (18.7%) | |
| HIV RNA 24 months post-2DR switch *‡: | ||
| pts <20 copies/ml | 53 (42.4%) | |
| pts <20 copies/mL target detected | 44 (35.2%) | |
| pts detectable >20 copies/ml | 28 (22.4%) | |
* Number (%), ** Median (IQR). 3TC: lamivudine; NRTIs: nucleoside reverse transcriptase inhibitors; NNRTI: nonnucleoside reverse transcriptase inhibitor; PI: protease inhibitor; DTG: dolutegravir; 2DR: two-drug antiretroviral therapy; pts: patients; HBcAb-positive: patients with antibodies against hepatitis B c antigen. †† Data available for 144 pts; ‡ Data available for 125 pts.